Benchmarking Q40 sequencing for sensitive and efficient detection of rare genomic variants
Next-generation sequencing can now catch rare cancer mutations using a third less genetic material, cutting costs while improving early cancer detection.
This rigorous benchmarking study using multiple gold-standard reference materials compared Q40 sequencing technology (Element AVITI, 99.99% accuracy) against conventional Q30 (Illumina NovaSeq), demonstrating that Q40 achieves equivalent accuracy at 33% lower sequencing depth while substantially improving detection of low-frequency somatic mutations and CNVs relevant to liquid biopsy and cancer genomics. Practical cost reductions of 2.2-31.7% per sample are projected, with important implications for clinical sequencing workflows.
What the study was
- Study design
- Benchmarking study using well-established reference materials
- Population
- Standardized DNA/RNA reference materials (Quartet, NIST-RM8398, SEQC2, MAQC, ERCC)
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Genome Biology
Why it surfaced
Published in Genome Biology (high-impact). Directly addresses cost and sensitivity limitations in clinical cancer genomics sequencing. Q40 improvement in low-VAF mutation detection is especially relevant to ctDNA liquid biopsy workflows.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.